Dec 19 2025 This Week in Cardiology

The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only . To read a partial transcript or to comment, visit: I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable? Limitations of Screening in Predicting First MI Sudden Death Due to Cardiac Arrhythmias UMC Amsterdam group (EHJ) II CELEBRATE Trial CELEBRATE Trial III SURPASS CVOT Trial Published Aug 01, 2025 This Week in Cardiology Podcast SURPASS-CVOT Trial REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link IV FDA Pulls Andexanet Alfa From the Market ANNEXA 4 ANNEXA I Richard Buka Tweet V Mandrola's Top Cardiovascular Stories of 2025 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. Questions or feedback, please contact news@medscape.net

You can listen to Dec 19 2025 This Week in Cardiology online on Radio and Podcast. Open the player on this page to stream the available audio.

Dec 19 2025 This Week in Cardiology is an episode from This Week in Cardiology by Medscape Podcasts.

This episode is 35:37 long.

This episode was published on Dec 19, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from This Week in Cardiology when more episodes are available from the podcast feed.